| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.087 | 0.05 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.05 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.05 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.05 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.05 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.05 |